HB0017 / Zhejiang Huahai Pharma - LARVOL DELTA

A Phase 2 Study to Explore the Efficacy and Safety of HB0017 Longer Dose Interval in Psoriasis Patients (clinicaltrials.gov) - P2 | N=200 | Not yet recruiting | Sponsor: Huabo Biopharm Co., Ltd.

New P2 trial • Dermatology • Immunology • Psoriasis

Study of Efficacy and Safety of HB0017 in Patients With Moderate to Severe Plaque Psoriasis (clinicaltrials.gov) - P3 | N=400 | Recruiting | Sponsor: Huabo Biopharm Co., Ltd.

New P3 trial • Dermatology • Immunology • Psoriasis

A Study to Evaluate the Efficacy and Safety of HB0017 in Patients With Moderate to Severe Plaque Psoriasis (clinicaltrials.gov) - P2 | N=160 | Completed | Sponsor: Huabo Biopharm Co., Ltd. | Not yet recruiting ➔ Completed

Trial completion • Dermatology • Immunology • Psoriasis • Psoriatic Arthritis

A Study to Evaluate the Efficacy and Safety of HB0017 in Patients With Moderate to Severe Plaque Psoriasis (clinicaltrials.gov) - P2 | N=160 | Not yet recruiting | Sponsor: Huabo Biopharm Co., Ltd.

New P2 trial • Dermatology • Immunology • Psoriasis • Psoriatic Arthritis

A Study of HB0017 in Patients With Moderate to Severe Plaque Psoriasis (clinicaltrials.gov) - P1 | N=30 | Completed | Sponsor: Huabo Biopharm Co., Ltd.

New P1 trial • Dermatology • Immunology • Psoriasis • Psoriatic Arthritis

A Study of Injection HB0017 in Adult Healthy Volunteers (clinicaltrials.gov) - P1; N=40; Completed; Sponsor: Huabo Biopharm Co., Ltd.; Active, not recruiting ➔ Completed

Trial completion

A Study of Injection HB0017 in Adult Healthy Volunteers (clinicaltrials.gov) - P1; N=40; Active, not recruiting; Sponsor: Huabo Biopharm Co., Ltd.; Not yet recruiting ➔ Active, not recruiting

Clinical • Enrollment closed

A Study of Injection HB0017 in Adult Healthy Volunteers (clinicaltrials.gov) - P1; N=40; Not yet recruiting; Sponsor: Huabo Biopharm Co., Ltd.

Clinical • New P1 trial

Huahai Pharmaceutical (600521.SH): HB0017 injection project approved for two new indications [Google translation] (Securities Star) - "Huahai Pharmaceutical (600521.SH) announced that recently, the company's subsidiaries Huabo Biomedical Technology (Shanghai) Co., Ltd. ('Huabo Bio') and Shanghai Huaaotai Biopharmaceutical Co., Ltd. ('Hua'aotai') received the 'Clinical Trial Notification' for the two new indications of the HB0017 injection project approved by the State Drug Administration ('SFDA')...HB0017 injection....Psoriatic arthritis...acceptance number: CXSL2000076....Ankylosing spondylitis...acceptance number: CXSL2000081."

Non-US regulatory • Immunology • Psoriasis • Psoriatic Arthritis